# Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

> **NCT06549335** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)

## Key facts

- **NCT ID:** NCT06549335
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549335, "Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06549335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*